Olympus (7733) AI Stock Analysis

• Market Cap: ¥2.05T
• Dividend Yield: 1.1%
• Average Volume (3M): 4.47M
• Price to Earnings (P/E): 18.4
• Beta (1Y): 0.75
• Revenue Growth: 0.59%
• EPS Growth: 557.87%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 7.97
• Shares Outstanding: 1,139,116,300
• 10 Day Avg. Volume: 4,286,550
• 30 Day Avg. Volume: 4,471,373
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,020.66
• Price Target Upside: 11.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 70 Outperform
• Price Target: ¥2,000.00 ▲(10.01% Upside)

Olympus's strong financial performance, particularly in profitability and cost management, is a key strength, though revenue growth and free cash flow generation pose challenges. Technical indicators suggest positive momentum, while valuation metrics indicate a fair market price. The absence of recent earnings call insights or notable corporate events limits additional context.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation, headquartered in Tokyo, Japan, is a global leader in the manufacturing and distribution of precision technology products, with a focus on medical and scientific equipment. The company is renowned for its innovations in optical and digital solutions, including endoscopes, microscopes, and other advanced medical imaging technologies. Olympus serves various sectors, including healthcare, life sciences, and industrial solutions, providing tools and systems that enhance the capabilities of professionals in these fields.

How the Company Makes Money

Olympus makes money primarily through the sale of its medical systems, scientific solutions, and industrial equipment. The largest revenue stream comes from its medical business, especially the sales of endoscopic devices and related surgical equipment used in minimally invasive procedures. The company also generates revenue from its scientific solutions division, which includes microscopes and other laboratory equipment used in research and development. Additionally, Olympus has a significant presence in the industrial sector, offering products such as non-destructive testing equipment and industrial microscopes. Partnerships with hospitals, research institutions, and industrial firms contribute significantly to its earnings, alongside continuous investment in research and development to innovate and maintain its competitive edge in technology and healthcare markets.

Olympus Financial Statement Overview

Summary

Olympus demonstrates strong profitability and efficient cost management, but faces challenges in revenue growth and free cash flow generation. The balance sheet is stable with improved leverage, supporting long-term financial health.

Income Statement

Olympus shows strong gross profit margins consistently above 68%, indicating efficient cost management. However, the net profit margin has decreased to 11.8% in the TTM, reflecting reduced profitability. The revenue growth rate is negative at -2.8% TTM, signaling a potential challenge in maintaining sales momentum.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.30, indicating a stable leverage position. Return on equity is at 15.8% TTM, showing decent profitability from shareholders' investments. The equity ratio is stable, suggesting a balanced capital structure.

Cash Flow

Operating cash flow remains robust, but free cash flow has decreased significantly by 29.8% TTM, which could impact future investments. The free cash flow to net income ratio is healthy at 0.76, indicating good cash generation relative to profits.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	969.02B	997.33B	925.75B	881.92B	750.12B	730.54B
Gross Profit	662.62B	683.70B	583.63B	596.85B	571.70B	459.53B
EBITDA	218.79B	231.90B	112.10B	254.58B	209.97B	140.42B
Net Income	112.26B	117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet
Total Assets	1.44T	1.43T	1.53T	1.51T	1.36T	1.18T
Cash, Cash Equivalents and Short-Term Investments	245.71B	252.53B	340.93B	169.33B	302.57B	217.48B
Total Debt	276.73B	229.10B	299.62B	340.06B	386.13B	355.26B
Total Liabilities	708.27B	681.09B	777.03B	867.07B	846.64B	785.54B
Stockholders Equity	732.65B	751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow
Free Cash Flow	101.37B	144.46B	-22.26B	27.87B	107.96B	64.89B
Operating Cash Flow	152.00B	190.46B	42.37B	98.49B	169.73B	124.12B
Investing Cash Flow	-67.82B	-65.47B	359.99B	-58.41B	-71.02B	-118.92B
Financing Cash Flow	-111.60B	-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1818.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Positive. The current price of 1818 is above the 20-day moving average (MA) of 1783.42, above the 50-day MA of 1760.01, and below the 200-day MA of 1984.78, indicating a neutral trend. The MACD of 16.68 indicates Negative momentum. The RSI at 54.22 is Neutral, neither overbought nor oversold. The STOCH value of 42.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7733	70 Outperform	¥2.05T	18.44	14.88%	1.10%	0.59%	557.87%
Sector *	51 Neutral	$7.93B	-0.35	-43.30%	2.25%	22.54%	-2.22%
TRUMF	―	$25.93B	30.91	9.17%	1.01%	―	―
AHICF	―	$4.95B	58.24	8.67%	0.88%	―	―
HOCPF	―	$49.16B	33.99	21.19%	0.80%	―	―
5FA	―	€1.48B	41.17	2.49%	―	―	―
SSMXF	―	$7.98B	25.07	10.48%	1.61%	―	―

Olympus Corporate Events

Olympus Completes Significant Share Repurchase

Olympus Corporation announced the completion of a share repurchase, acquiring 13,675,400 common shares for approximately JPY 24 billion between August 1 and August 31, 2025. This move is part of a broader strategy approved by the Board of Directors to repurchase up to 36 million shares, aiming to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen1849.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports Decline in Q1 Financial Performance Amid Business Adjustments

Olympus Corporation reported a significant decline in its financial performance for the three months ending June 30, 2025, with revenue and profits dropping compared to the previous year. The company’s revenue fell by 12.1%, and operating profit decreased by 39.6%, largely due to the classification of its Orthopedic Business as a discontinued operation. Despite these challenges, Olympus has revised its full-year forecast, expecting minimal revenue growth but a notable decline in profits, reflecting ongoing adjustments in its business operations.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Progress in Share Repurchase Program

Olympus Corporation announced the status of its share repurchase program, having repurchased 2,114,500 common shares for approximately JPY 3.83 billion between July 28 and July 31, 2025. This move is part of a broader plan approved by the Board of Directors to repurchase up to 36 million shares, valued at a maximum of JPY 50 billion, by October 31, 2025, which is intended to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Partners with Revival Healthcare for Endoluminal Robotics Venture

Olympus Corporation has announced a joint venture with Revival Healthcare Capital to develop endoluminal robotic surgery products through Swan EndoSurgical, Inc. This strategic investment aims to strengthen Olympus’s position in the MedTech industry by capitalizing on the growing market for minimally invasive surgical solutions, with potential investments reaching up to $458 million over six years. The venture underscores Olympus’s commitment to advancing medical technology and improving patient outcomes.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.